Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Aura Biosciences, Inc. have bought $0 and sold $1.06M worth of Aura Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Aura Biosciences, Inc. have bought $21.79M and sold $473,027 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,560,000 shares for transaction amount of $14.04M was made by Matrix Capital Management Company, LP (10 percent owner) on 2023‑11‑09.
2024-11-18 | Sale | Chief Medical Officer | 11,822 0.0244% | $9.36 | $110,663 | -2.36% | ||
2024-10-29 | Sale | See Remarks | 9,200 0.0186% | $10.74 | $98,788 | -13.07% | ||
2024-10-29 | Sale | Vice President, Finance | 553 0.0011% | $10.74 | $5,938 | -13.07% | ||
2024-10-18 | Sale | See Remarks | 24,992 0.0517% | $12.04 | $300,839 | -19.34% | ||
2024-10-18 | Sale | Chief Financial Officer | 25,131 0.0519% | $12.03 | $302,361 | -19.34% | ||
2024-10-16 | Sale | Chief Technology Officer | 7,383 0.0163% | $9.85 | $72,723 | -0.98% | ||
2024-01-23 | Sale | See Remarks | 15,853 0.0323% | $7.64 | $121,141 | +4.64% | ||
2024-01-23 | Sale | Chief Financial Officer | 6,609 0.0135% | $7.64 | $50,521 | +4.64% | ||
2023-11-09 | 10 percent owner | 1.56M 5.251% | $9.00 | $14.04M | +14.06% | |||
2023-11-08 | director | 19,601 0.0517% | $7.30 | $143,087 | +11.46% | |||
2023-11-07 | director | 123,000 0.3185% | $7.17 | $881,910 | +12.73% | |||
2023-11-06 | Sale | See Remarks | 7,449 0.0211% | $12.03 | $89,611 | -28.10% | ||
2023-11-06 | Sale | Chief Financial Officer | 3,900 0.0111% | $12.07 | $47,054 | -28.10% | ||
2023-10-30 | Sale | See Remarks | 9,586 0.0229% | $6.83 | $65,478 | +7.23% | ||
2023-10-30 | Sale | Chief Financial Officer | 3,385 0.0081% | $6.82 | $23,091 | +7.23% | ||
2023-10-04 | director | 6,566 0.0178% | $8.61 | $56,512 | -7.88% | |||
2023-10-03 | director | 13,500 0.0352% | $8.27 | $111,663 | -6.59% | |||
2023-01-06 | director | 904 0.0024% | $10.51 | $9,501 | -3.81% | |||
2023-01-05 | director | 396 0.001% | $10.00 | $3,960 | -2.60% | |||
2022-12-28 | director | 2,000 0.0066% | $9.75 | $19,500 | +3.45% |
de los Pinos Elisabet | See Remarks | 320647 0.6419% | $8.83 | 0 | 6 | |
Hopkins Janet Jill | Chief Medical Officer | 151693 0.3037% | $8.83 | 0 | 1 | |
Feder Julie B | Chief Financial Officer | 134276 0.2688% | $8.83 | 0 | 5 | |
Plavsic Mark | Chief Technology Officer | 121132 0.2425% | $8.83 | 0 | 1 | |
Elazzouzi Amy | Vice President, Finance | 39443 0.079% | $8.83 | 0 | 1 | |
Matrix Capital Management Company, LP | 10 percent owner | 6922870 13.8592% | $8.83 | 3 | 0 | <0.0001% |
Medicxi Ventures Management (Jersey) Ltd | director | 2969352 5.9445% | $8.83 | 1 | 0 | <0.0001% |
Johnson David Michael | director | 135667 0.2716% | $8.83 | 9 | 0 | <0.0001% |
Rich Cadmus | See Remarks | 24578 0.0492% | $8.83 | 0 | 1 | |
De Rosch Mark | Chief Operating Officer | 16385 0.0328% | $8.83 | 0 | 1 |
Matrix Capital Management Company, L.P. | $54.34M | 13.97 | 6.92M | 0% | +$0 | 0.51 | |
Eventide Asset Management | $45.55M | 11.71 | 5.8M | 0% | +$0 | 0.74 | |
Adage Capital Partners Gp L L C | $35.05M | 9.01 | 4.46M | +5.68% | +$1.88M | 0.06 | |
Citadel Advisors LLC | $28.86M | 7.42 | 3.68M | +1.24% | +$353,077.30 | 0.02 | |
Medicxi Growth I Lp | $23.86M | 6.14 | 3.04M | 0% | +$0 | 5.31 | |
BlackRock | $19.19M | 4.93 | 2.44M | +16.49% | +$2.72M | <0.0001 | |
The Vanguard Group | $13.25M | 3.41 | 1.69M | -2.49% | -$337,714.84 | <0.0001 | |
Franklin Templeton Investments | $11.41M | 2.93 | 1.45M | +142.18% | +$6.7M | <0.01 | |
Nantahala Capital Management Llc | $10.38M | 2.67 | 1.32M | 0% | +$0 | 0.48 | |
Goldman Sachs | $7.82M | 2.01 | 996,643 | -3.92% | -$319,149.62 | <0.01 | |
Regency Capital Management Inc De | $6.16M | 1.59 | 785,136 | +11.37% | +$629,271.74 | 4.01 | |
Geode Capital Management | $6.13M | 1.58 | 781,190 | +15.54% | +$824,861.98 | <0.01 | |
T. Rowe Price | $4.68M | 1.2 | 595,540 | -9.72% | -$503,702.11 | <0.01 | |
State Street | $4.47M | 1.15 | 569,804 | +12.55% | +$498,804.66 | <0.0001 | |
Long Focus Capital Management Llc | $3.89M | 1 | 495,422 | +45.53% | +$1.22M | 0.46 | |
Ensign Peak Advisors Inc | $2.8M | 0.72 | 357,222 | 0% | +$0 | 0.01 | |
Northern Trust | $2.33M | 0.6 | 296,323 | +19.28% | +$375,952.27 | <0.0001 | |
Fidelity Investments | $2.31M | 0.6 | 294,654 | -17.47% | -$489,690.87 | <0.0001 | |
Jefferies Financial Group | $1.75M | 0.45 | 222,497 | New | +$1.75M | 0.03 | |
Dimensional Fund Advisors | $1.64M | 0.42 | 208,664 | +17.41% | +$242,926.04 | <0.0001 | |
PLATINUM INVESTMENT MANAGEMENT LTD | $1.41M | 0.36 | 180,145 | 0% | +$0 | 0.02 | |
Verition Fund Management Llc | $1.19M | 0.31 | 151,681 | -0.33% | -$3,964.25 | 0.01 | |
Two Sigma | $894,029.00 | 0.23 | 113,889 | +168.69% | +$561,290.92 | <0.01 | |
Levin Capital Strategies | $872,920.00 | 0.22 | 111,200 | +11.2% | +$87,920.00 | 0.09 | |
Td Asset Management Inc | $847,109.00 | 0.22 | 107,912 | 0% | +$0 | <0.01 | |
Charles Schwab | $834,015.00 | 0.21 | 106,244 | +16.18% | +$116,148.54 | <0.0001 | |
D. E. Shaw & Co. | $749,243.00 | 0.19 | 95,445 | +58.91% | +$277,740.76 | <0.01 | |
BNY Mellon | $741,651.00 | 0.19 | 94,478 | +4.64% | +$32,914.99 | <0.0001 | |
Morgan Stanley | $681,821.00 | 0.18 | 86,856 | +4.94% | +$32,098.72 | <0.0001 | |
Connor Clark & Lunn Investment Management Ltd | $562,735.00 | 0.15 | 71,686 | +454.76% | +$461,297.32 | <0.01 | |
Millennium Management LLC | $555,128.00 | 0.14 | 70,717 | New | +$555,128.00 | <0.0001 | |
Nuveen | $551,455.00 | 0.14 | 70,249 | 0% | +$0 | <0.0001 | |
Ubs Oconnor Llc | $528,501.00 | 0.14 | 67,325 | -25.19% | -$177,998.67 | 0.02 | |
TBH Global Asset Management | $473,530.00 | 0.12 | 60,322 | 0% | +$0 | 0.1 | |
Renaissance Technologies | $448,000.00 | 0.12 | 57,100 | +100.35% | +$224,392.29 | <0.01 | |
The Manufacturers Life Insurance Company | $441,625.00 | 0.11 | 56,258 | +0.57% | +$2,512.00 | <0.0001 | |
New York Life Investment Management Llc | $366,862.00 | 0.09 | 46,734 | New | +$366,862.00 | <0.01 | |
RhumbLine Advisers | $356,947.00 | 0.09 | 45,472 | +14.01% | +$43,872.64 | <0.0001 | |
Exchange Traded Concepts, LLC | $299,831.00 | 0.08 | 38,195 | +156.36% | +$182,873.75 | 0.01 | |
Marshall Wace | $292,083.00 | 0.08 | 37,208 | New | +$292,083.00 | <0.0001 | |
UBS | $287,671.00 | 0.07 | 36,646 | +17.98% | +$43,834.39 | <0.0001 | |
Bank of America | $274,224.00 | 0.07 | 34,933 | -1.49% | -$4,136.95 | <0.0001 | |
Alps Advisors Inc | $272,364.00 | 0.07 | 34,696 | +3.08% | +$8,132.61 | <0.01 | |
Two Sigma Advisers LP | $247,275.00 | 0.06 | 31,500 | New | +$247,275.00 | <0.0001 | |
Values First Advisors, Inc. | $214,232.00 | 0.06 | 27,291 | +149.71% | +$128,440.29 | 0.05 | |
Barclays | $199,000.00 | 0.05 | 25,394 | -33.47% | -$100,111.25 | <0.0001 | |
JPMorgan Chase | $190,636.00 | 0.05 | 24,285 | +32.27% | +$46,510.94 | <0.0001 | |
Letko Brosseau | $166,420.00 | 0.04 | 21,200 | New | +$166,420.00 | <0.01 | |
Jane Street Capital | $165,023.00 | 0.04 | 21,022 | -26.97% | -$60,955.36 | <0.0001 | |
Susquehanna International Group | $144,393.00 | 0.04 | 18,394 | +69.91% | +$59,408.84 | <0.0001 |